Furst D E, Dromgoole S H, Fow S, Landaw E M
J Clin Pharmacol. 1983 Nov-Dec;23(11-12):557-62. doi: 10.1002/j.1552-4604.1983.tb01803.x.
We could find no significant differences in the kinetics of tolmetin when comparing five rheumatoid arthritis patients with moderate disease activity with a carefully matched group of normal healthy volunteers. Further, there were no discernible clinically significant differences in the kinetics of tolmetin when comparing a single dose to one week of therapy. These results, although limited by the small number of subjects involved and the large interpatient variability, suggest that it may be possible to extrapolate pharmacokinetic data from normals to patients with moderately active disease.
在将五名中度疾病活动度的类风湿关节炎患者与一组精心匹配的正常健康志愿者进行比较时，我们未发现托美汀动力学方面的显著差异。此外，在比较单剂量给药与一周治疗的托美汀动力学时，也未发现明显的临床显著差异。尽管这些结果受限于所涉及的受试者数量较少以及患者间的较大变异性，但表明从正常人群推断中度活动性疾病患者的药代动力学数据可能是可行的。
